Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Stephanie Guize

Physician Assistant West Amherst, NY Physician Assistant

NPI 1104933886 CMS profile 10414733

3950 E Robinson Rd, Suite 207, West Amherst, NY 14228

Open in the dashboard

General payments

$6,439

378 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephanie Guize of West Amherst, NY is reported in the CMS Open Payments database as having received $6,439 across 378 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,129 67
2024 General $1,839 96
2023 General $1,342 87
2022 General $1,335 69
2021 General $793 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephanie Guize
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Stephanie Guize were reported at $1,129. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Stephanie Guize Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $793 $132 $37–$438 $132
2022 $1,335 $155 $48–$522 $149
2023 $1,342 $167 $52–$557 $160
2024 $1,839 $178 $55–$600 $164
2025 $1,129 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,095 87 payments
  2. Lilly USA, LLC $708 53 payments
  3. AbbVie, Inc. $535 22 payments
  4. Pfizer Inc. $530 33 payments
  5. Astellas Pharma US Inc $483 22 payments
  6. GlaxoSmithKline, LLC. $403 25 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $341 20 payments
  8. AstraZeneca Pharmaceuticals LP $253 10 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $217 12 payments
  10. Abbott Laboratories $202 4 payments
  11. Other $1,672 90 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,349 377 payments
  2. Education $90 1 payment
Products named General payments · program years 2021–2025
  1. Ozempic $458 38 payments
  2. RYBELSUS $458 38 payments
  3. NURTEC ODT $353 22 payments
  4. Wegovy $352 24 payments
  5. JARDIANCE $336 23 payments
  6. TRELEGY ELLIPTA $333 20 payments
  7. MOUNJARO $292 25 payments
  8. UBRELVY $287 8 payments
  9. Veozah $255 13 payments
  10. Saxenda $236 22 payments
  11. Other $4,550 236 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 79 drugs

Part D claims

3,686

Median for Physician Assistant: 241

Drug cost

$345,693

Median for Physician Assistant: $4,110

Branded share of claims

18.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 90 $110,919
Jardiance Empagliflozin Brand 31 $42,380
Trulicity Dulaglutide Brand 29 $34,046
Eliquis Apixaban Brand 38 $30,364
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 31 $21,215
Mounjaro Tirzepatide Brand 17 $17,123
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 21 $11,752
Synjardy Empagliflozin/Metformin Hcl Brand 14 $10,338
Repatha Sureclick Evolocumab Brand 11 $6,012
Atorvastatin Calcium Generic 353 $5,874

The 10 drugs with the highest cost, of 79 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$10,257

Of which drugs: $1,624

Medicare patients

71

Average age 70

Services billed

190

49 women, 22 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 38%
Chronic kidney disease 30%
Diabetes 28%
COPD 27%
Depression 25%
Ischemic heart disease 24%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $158
$158 — —
JARDIANCE
  • Lilly USA, LLC $79
  • Boehringer Ingelheim Pharmaceuticals, Inc. $58
$137 31 —
Veozah
  • Astellas Pharma US Inc $131
$131 — —
MOUNJARO
  • Lilly USA, LLC $122
$122 17 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $92
$92 31 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

378 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record